WINTER PARK, Fla., Nov. 17 -- LaserSight Inc. reported that it has been granted pre-market approval by the US Food and Drug Administration for the use of its excimer laser system, the LaserScan LSX, in performing photorefractive keratectomy to treat low to moderate myopia. The approval will allow the company to market the system for laser refractive vision correction procedures in the US. LaserSight has also filed a PMA supplement for the use of the system to treat nearsightedness with astigmatism, and expects to file a PMA for hyperopia and hyperopic astigmatism in the middle of next year.